Treatment of c1013g/cxcr4-associated waldenstrom's macroglobulinemia with an anti-cxcr4 antibody
AssigneeBristol-Myers Squibb Company
InventorsIrene M. Ghobrial, Aldo M. Roccaro, Josephine M. Cardarelli, Antonio Sacco
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method for treating a subject afflicted with Waldenström's macroglobulinemia (WM) comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a WM cell. The disclosure also provides a therapeutic regimen for treating a patient afflicted with C1013G/CXCR4-associated WM.
Claims35
A method for treating a subject afflicted with C1013G/CXCR4-associated Waldenström's macroglobulinemia comprising administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a C-X-C chemokine receptor type 4 (CXCR4) receptor expressed on the surface of a Waldenström's macroglobulinemia cell.
A method for treating a subject afflicted with C1013G/CXCR4-associated Waldenström's macroglobulinemia, which method comprises:
- (a) selecting a subject that is a suitable candidate for treatment, the selecting comprising:
- (i) assessing whether cells in a test tissue sample obtained from Waldenström's macroglobulinemia tissue in the subject carry the C1013G mutation in the C-X-C chemokine receptor type 4 (CXCR4) gene;
- and
- (ii) selecting the subject as a suitable candidate based on a determination that the Waldenström's macroglobulinemia cells carry the C1013G mutation in the CXCR4 gene;
- and
- (b) administering to the selected subject a therapeutically effective amount of an anti-CXCR4 antibody or an antigen-binding portion thereof that specifically binds to a CXCR4 receptor expressed on the surface of a C1013G/CXCR4-associated Waldenström's macroglobulinemia cell.
A method for treating a subject afflicted with C1013G/CXCR4-associated Waldenström's macroglobulinemia, which method comprises administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to a C-X-C chemokine receptor type 4 (CXCR4) receptor expressed on the surface of a C1013G/CXCR4-associated Waldenström's macroglobulinemia cell, the subject having been selected on the basis that the Waldenström's macroglobulinemia cells of the subject are determined to carry the C1013G mutation in the CXCR4 gene.
5-9. (canceled)
(canceled)
(canceled)
(canceled)
26-27. (canceled)
The method of claim 26, wherein the anti-CXCR4 antibody or antigen-binding portion thereof is administered at a dosing schedule of once per week, once every two weeks, once every three weeks, or once a month.
(canceled)
33-34. (canceled)
(canceled)
A method for selecting a Waldenström's macroglobulinemia patient for treatment with an antibody or an antigen-binding portion thereof that specifically binds to a C-X-C chemokine receptor type 4 (CXCR4) receptor expressed on the surface of a Waldenström's macroglobulinemia cell, which method comprises:
- (a) assessing whether cells in a test tissue sample obtained from a Waldenström's macroglobulinemia patient carry the C1013G mutation in the CXCR4 gene;
- and
- (b) selecting the patient for treatment based on a determination that the Waldenström's macroglobulinemia cells carry the C1013G mutation in the CXCR4 gene.
40-41. (canceled)
Dependencies are inferred from the claim text.